FDA Sets Patent Review Clock for LAZCLUZE Drug
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for LAZCLUZE, a human drug product, which helps the patent owner apply for extra patent time. This means the company behind LAZCLUZE can extend their patent protection, giving them more time to sell their drug exclusively. If you’re in the drug business or follow patents, this update signals important timing for patent extensions and market control.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent extension possible for LAZCLUZE
The FDA has set the regulatory review period for LAZCLUZE, a human drug product. This lets the patent owner submit an application to the U.S. Patent and Trademark Office to extend their patent, which can give the company more time to sell LAZCLUZE exclusively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in